These findings underscore the potential of targeting YTHDF1 as a promising approach in cancer therapeutics, as it is capable of modulating both tumor cell‐intrinsic factors and immune‐related aspects of the tumor microenvironment. The gene discussed is YTHDF1; the disease is neoplasm.